Skip to Content

Posts tagged with "Cardiovascular Disease"

  • Cardiovascular Disease

    Inhaled Nanoparticles – Good Ones, That Is

    Never give up on drug delivery ideas – that’s one of the big points I get out of this paper. The authors, part of a multi-center team from sites in Italy and Germany, have previously shown that calcium phosphate nanoparticles could be a good carrier for delicate cargo such as microRNAs. Such things tend to… Read More
  • Cardiovascular Disease

    AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking about anything to do with the response to levels of fuel like glucose or fatty acids and determination of their downstream fates, then AMPK is almost certainly crucial. Activating the enzyme se… Read More
  • Cardiovascular Disease

    Hold On, Merck’s CETP Inhibitor Actually Works?

    Well, maybe. I have to admit that my first reaction was disbelief. Merck has come out this morning with a statement that its long-running outcomes trial with anacetrapib, their cholesteryl ester transfer protein (CETP) inhibitor, had positive results. Specifically, they say that the trial. . . . . .met its primary endpoint, significantly reducing m… Read More
  • Cardiovascular Disease

    Two Diabetes Drug Mysteries

    Here are some data to file under “Drugs do things that we don’t expect”. The SGLT-2 inhibitors are a class of diabetes medications that work by inhibiting the sodium/glucose transporter 2 protein in the kidneys. That keeps glucose from being reabsorbed there; instead, more of it is removed in the urine, and that lowers circulating… Read More
  • Cardiovascular Disease

    Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you haven’t been doing this stuff long enough”. Well, it’s pretty hard to hold your breath across a full tox study, but you know what I mean. There are… Read More
  • Cardiovascular Disease

    Now This Is A Drug That Does Not Work

    I’ve already written about how Eli Lilly’s inhibitor of cholesteryl ester transfer protein (CETP) did not work in the clinic. Now that the data from their failed trial have been published in the NEJM, though, it’s worth taking a look at a few graphs (first pointed out to me on Twitter by Sek Kathiresan. Shown are… Read More
  • Cardiovascular Disease

    A Clinical Trial Torpedoed By Fraud and Incompetence

    Via @AndyBiotech on Twitter, here’s a story on some very troubling developments in offshore clinical trials. That Cardiobrief article is referring to this letter in NEJM, and the subject is the NIH’s trial of spironolactone in heart failure patients. The TOPCAT trial enrolled 3445 participants  in 6 countries (1151 in the US, 326 i… Read More
  • Cardiovascular Disease

    The Genomics Revolution Shows Up Late, But Shows Up

    Robert Plenge has an excellent overview of the PCSK9 story up on his site; I recommend it. His take may sound different from mine at first, but I think we’re actually in agreement on a lot of important points. I said that “PCSK9 is about as compelling a story as we’re likely to see in… Read More
  • Cardiovascular Disease

    What PCSK9 Is Telling Us About Drug Discovery

    Friday’s news about the real-world effects of PCSK9 drugs continue to reverberate. It’s worth going into the topic again, but from a wider view of genomics-driven medicine, because this is currently one of the biggest strategies for drug discovery in the industry. The reasoning behind this is pretty compelling. If you comb through the h… Read More
  • Business and Markets

    PCSK9: Real World Data Arrives, Unfortunately

    So, PCSK9. A wonderful story of genetics-based drug discovery, and a huge commercial opportunity. People with loss-of-function PCSK9 genes have very low LDL cholesterol, with no other ill effects, and people with gain-of-function mutations have chronically high cholesterol. That’s about as good as the validation gets, so a number of drug co… Read More
123...